Method paper: new version 6.1 comes into force

24 January 2022 - The innovations concern, among other things, the procedure for evidence searches for medical guidelines. New concept ...

Read more →

The G-BA classifies three drugs as reserve antibiotics

20 January 2022 - The Federal Joint Committee (G-BA) today exempted three drugs classified as reserve antibiotics from the regular early ...

Read more →

Immunotherapy with blinatumomab improves the chances of survival in very rare childhood blood cancer

20 January 2022 - The Federal Joint Committee (G-BA) today classified the additional benefit of the active ingredient blinatumomab as significant ...

Read more →

Early benefit assessment for new drugs 2021: G-BA sets a record with 146 completed procedures

10 January 2022 - At the beginning of the year, the Federal Joint Committee (G-BA) took stock of its assessment of ...

Read more →

Hyposensitisation with AR101 in peanut allergy: proof of lesser benefit

17 January 2022 - In the patient-relevant outcomes, there are only disadvantages for 4- to 17-year-olds compared to a pure peanut-avoiding ...

Read more →

Orphan drugs: privilege of "fictitious" additional benefit not justified

12 January 2022 - Drugs for orphan diseases should also go through a regular benefit assessment procedure when they enter the ...

Read more →

Daratumumab in multiple myeloma: reassessment results in hint of considerable added benefit

3 January 2022 - Janssen applied for a new early benefit assessment due to new scientific findings.  ...

Read more →

Nivolumab for the adjuvant treatment of oesophageal carcinoma: indication of minor added benefit

1 December 2021 - Those affected develop fewer relapses than if they wait and see.  ...

Read more →

Upadacitinib in atopic dermatitis: additional benefit for adults at high dose

1 December 2021 - Women should expect more serious adverse effects than men.  ...

Read more →

Call for a central portal for clinical study reports

1 December 2021 - In an open-access publication in the Journal of European CME, two authors from IQWiG argue that ...

Read more →

Germany's Government to be eyes backdated drug price cuts

24 November 2021 - Germany's prospective three-party government plans to cut prices retroactively for recently-launched prescription drugs to keep health ...

Read more →

Drugs against rare diseases: Libmeldy gene therapy shows additional benefits - Zolgensma cell therapy, on the other hand, does not

4 November 2021 - The Federal Joint Committee (G-BA) today assessed the additional benefit of two active ingredients against very rare, ...

Read more →

Nivolumab and ipilimumab: added benefit in pleural mesothelioma with non-epithelioid tumour histology

1 October 2021 - For the first time, a pure antibody combination has been approved as a first-line therapy for ...

Read more →

Adjuvant treatment for NSCLC: osimertinib mesylate may benefit certain people

1 October 2021 - Hint of considerable additional benefit if, after complete tumour resection, adjuvant platinum-based chemotherapy has already been ...

Read more →

With remdesivir, the Federal Joint Committee assesses the additional benefit of an anti-viral COVID-19 drug for the first time

16 September 2021 - Do patients with COVID-19 have a better chance of surviving and recovering faster if they are treated ...

Read more →